

Therapeutics Advisory Group Update - Issue 26 – November 2023

All recommendations discussed at the **November** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **November 2023**. Please share within your organisation as appropriate

Commissioning Summary

<p>Formulary application - Bimekizumab for treating active psoriatic arthritis as per TA916</p>	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
<p>Formulary application - Bimekizumab for treating axial spondyloarthritis as per TA918</p>	
<p>Formulary application - Tofacitinib for treating active ankylosing spondylitis as per TA920</p>	
<p>Formulary application - Mirikizumab (Omvoh®) for treating moderately to severely active ulcerative colitis as per TA925</p>	
<p>Commissioning Review - Tetrabenazine tablets (Xenazine® 25) for hyperkinetic motor disorders with Huntington's chorea</p>	<ul style="list-style-type: none"> ADVICE – Specialist will initiate and retain patient until stable. Guidance document in development to support prescribers
<p>Commissioning Review – LimbO protectors - Waterproof protectors to wear in shower/bath to protect casts, dressings and PICC lines.</p>	<ul style="list-style-type: none"> BLACK – not commissioned. No prescribing primary or secondary care
<p>Commissioning Review - Fludrocortidone tape (previously Haelan) - Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions</p>	<ul style="list-style-type: none"> ADVICE – Specialist initiation / recommendation for licensed indications BLACK – not commissioned. No prescribing primary or secondary care for unlicensed indications
<p>Prescribing Guidance - Methadone for use in pain management – Oct 2023</p>	<ul style="list-style-type: none"> To be published and circulated in due course
<p>Local PGDs for information</p>	<ul style="list-style-type: none"> Triamcinolone Acetonide 40mg/mL Injection Methylprednisolone 40mg/mL Injection Lidocaine Hydrochloride 1% and 2% Injection
<p>Netformulary Updates</p> <p>We have several sections live on Netformulary. If you have any formulary queries, please remember to check there first before emailing the generic inbox</p>	

Shared Care Updates

<ul style="list-style-type: none"> Dementia – routine review 	<ul style="list-style-type: none"> To discuss suggested updates further with NSFT Will return to TAG in due course
<ul style="list-style-type: none"> Azathioprine for use in Ulcerative Colitis & Crohn's Disease – update merges local agreement with RMOC template 	<ul style="list-style-type: none"> To update monitoring requirements based on existing local agreement To return to TAG for final sign-off

NICE Guidance – acknowledged by the TAG

NG234 – September 2023 - Spinal metastases and metastatic spinal cord compression
NG192 – Mar 2021, updated September 2023 - Caesarean birth
NG50 – July 2016, updated September 2023 - Cirrhosis in over 16s: assessment and management
NG148 – December 2019, updated September 2023 - Acute kidney injury: prevention, detection and management
NG235 – September 2023 - Intrapartum care
CG122 – April 2011, updated October 2023 - Ovarian cancer: recognition and initial management
CG148 – August 2012, updated October 2023 - Urinary incontinence in neurological disease: assessment and management
NG98 – June 2018, updated October 2023 - Hearing loss in adults: assessment and management
NG127 – May 2019, updated October 2023 - Suspected neurological conditions: recognition and referral
NG12 – June 2015, updated October 2023 - Suspected cancer: recognition and referral
NG145 – November 2019, updated October 2023 - Thyroid disease: assessment and management
NG236 – October 2023 - Stroke rehabilitation in adults

NICE Technology Appraisals – ICB Commissioning Responsibility

TA875 – March 2023, updated September 2023 - Semaglutide (Wegovy®) for managing overweight and obesity	Red Specialist Use Only – to be supplied by Tier 3 service. No prescribing in primary care
TA916 – October 2023 - Bimekizumab (Bimzelx®) for treating active psoriatic arthritis (30 day implementation)	Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care (see earlier applications)
TA918 – October 2023 - Bimekizumab (Bimzelx®) for treating axial spondyloarthritis (30 day implementation)	
TA920 – October 2023 - Tofacitinib (Xeljanz®) for treating active ankylosing spondylitis (30 day implementation)	
TA925 – October 2023 - Mirikizumab (Omvo®) for treating moderately to severely active ulcerative colitis (30 day implementation)	
TA919 – October 2023 - Rimegepant (Vyndura®) for treating migraine	
TA922 – October 2023 - Daridorexant (QUVIVIQ®) for treating long-term insomnia	BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required
TA924 – October 2023 - Tirzepatide (Mounjaro®) for treating type 2 diabetes	
TA926 – October 2023 - Baricitinib (Olumiant®) for treating severe alopecia areata	

NICE Technology Appraisals – NHS England Commissioning Responsibility

<p>TA913 – September 2023 - Mavacamten (Camzyos®) for treating symptomatic obstructive hypertrophic cardiomyopathy</p>	<p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>TA914 – September 2023 - Pembrolizumab (Keytruda®) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency</p>	
<p>TA915 – October 2023 - Pegunigalsidase alfa (Elfabrio®) for treating Fabry disease</p>	
<p>TA921 – October 2023 - Ruxolitinib (Jakavi®) for treating polycythaemia vera</p>	
<p>TA927 – October 2023 - Glofitamab (Columvi®) for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments</p>	
<p>TA917 – October 2023 - Daratumumab (Darzalex®) with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable</p>	

NICE Technology Appraisals – Terminated Appraisals

<p>TA923 – October 2023 - Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus</p>	<p>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</p>
--	--

NICE NHS England Highly Specialised Technologies

<p>HST28 – September 2023 - Birch bark extract for treating epidermolysis bullosa</p>	<p>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
---	--

Useful Information

Next meeting	Wednesday 10th January 2024
Deadline for agenda submissions	Tuesday 2nd January 2024